Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Other Non-Current Assets (2016 - 2025)

Ultragenyx Pharmaceutical has reported Other Non-Current Assets over the past 11 years, most recently at $60.0 million for Q4 2025.

  • Quarterly Other Non-Current Assets fell 4.76% to $60.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $60.0 million through Dec 2025, down 4.76% year-over-year, with the annual reading at $60.0 million for FY2025, 4.76% down from the prior year.
  • Other Non-Current Assets was $60.0 million for Q4 2025 at Ultragenyx Pharmaceutical, up from $57.9 million in the prior quarter.
  • Over five years, Other Non-Current Assets peaked at $63.0 million in Q4 2024 and troughed at $8.9 million in Q1 2021.
  • The 5-year median for Other Non-Current Assets is $38.1 million (2022), against an average of $38.6 million.
  • Year-over-year, Other Non-Current Assets skyrocketed 222.45% in 2021 and then decreased 4.76% in 2025.
  • A 5-year view of Other Non-Current Assets shows it stood at $20.6 million in 2021, then soared by 135.13% to $48.3 million in 2022, then grew by 19.34% to $57.7 million in 2023, then grew by 9.21% to $63.0 million in 2024, then decreased by 4.76% to $60.0 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Other Non-Current Assets are $60.0 million (Q4 2025), $57.9 million (Q3 2025), and $60.1 million (Q2 2025).